|1.||Wiemer, Erik A C: 1 article (09/2014)|
|2.||van der Biessen, Diane A J: 1 article (09/2014)|
|3.||de Jonge, Maja J A: 1 article (09/2014)|
|4.||Loferer, Hannes: 1 article (09/2014)|
|5.||de Bruijn, Peter: 1 article (09/2014)|
|6.||Naus, Nicole: 1 article (09/2014)|
|7.||Lamers, Cor H J: 1 article (09/2014)|
|8.||Mathijssen, Ron H J: 1 article (09/2014)|
|9.||Burger, Herman: 1 article (09/2014)|
|10.||Cirstea, D: 1 article (12/2013)|
12/01/2013 - "RGB-286638 treatment resulted in MM cytotoxicity in vitro associated with inhibition of MM tumor growth and prolonged survival in vivo. "
09/15/2014 - "Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors."
09/15/2014 - "RGB-286638 is a multitargeted inhibitor with targets comprising the family of cyclin-dependent kinases (CDK) and a range of other cancer-relevant tyrosine and serine/threonine kinases. "
|3.||Cyclin-Dependent Kinases (cdk Proteins)
|4.||Protein-Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)